Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Skin Itching

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    174 result(s) found for: Skin Itching. Displaying page 1 of 9.
    1  2  3  4  5  6  7  8  9  Next»
    EudraCT Number: 2005-004464-24 Sponsor Protocol Number: P04608 Start Date*: 2006-04-21
    Sponsor Name:Integrated Therapeutics Group, Inc
    Full Title: A Double-blind, Placebo-controlled, Randomized, Parallel-group Multicenter Study of Mometasone Furoate Nasal Spray on Sleep Disturbances and Daytime Somnolence in Subjects with Symptomatic Seasonal...
    Medical condition: Seasonal Allergic Rhinitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) GB (Completed) NL (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-002763-25 Sponsor Protocol Number: NT2013/Orv/Prot001 Start Date*: 2013-10-11
    Sponsor Name:NeRRe Therapeutics Ltd
    Full Title: A randomised, double-blind, placebo-controlled study to evaluate the efficacy of two different dose levels of orvepitant (10 and 30 mg) compared with placebo on EGFRi-induced intense pruritus in on...
    Medical condition: Intense pruritus, in oncology subjects, induced by EGFRi
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004858 10023084 Itching LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-000610-26 Sponsor Protocol Number: MK-4117-202 Start Date*: 2017-02-09
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III, Multicenter, Open-Label Long-Term Trial to Study the Efficacy and Safety of MK-4117 in Japanese Subjects With Eczema/Dermatitis and Dermal Pruritus.
    Medical condition: Eczema/dermatitis and the dermal pruritus (itchy skin disease)
    Disease: Version SOC Term Classification Code Term Level
    19.1 10040785 - Skin and subcutaneous tissue disorders 10012431 Dermatitis PT
    19.1 10040785 - Skin and subcutaneous tissue disorders 10014184 Eczema PT
    19.1 10040785 - Skin and subcutaneous tissue disorders 10037090 Pruritus cutaneous LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-000865-13 Sponsor Protocol Number: PMLD17102005 Start Date*: 2006-04-17
    Sponsor Name:Univ.Clinic of Dermatology
    Full Title: Evaluation of the impact from Polypodium leukotomos Extract on the Prophylaxis of Polymorphic Light Eruption (PMLE) An investigator initiated, prospective, open label study with an in Austria reg...
    Medical condition: Evaluation of the impact from Polypodium leukotomos Extract on the Prophylaxis of Polymorphic Light Eruption (PMLE) An investigator initiated, prospective, open label study with an in Austria reg...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2013-001601-85 Sponsor Protocol Number: UKM10_0037 Start Date*: 2014-02-14
    Sponsor Name:University Hospital Münster
    Full Title: Aprepitant in histamine-refractory chronic pruritus: a multicenter, randomized, double-blind, placebo-controlled, cross-over, phase II trial
    Medical condition: Patients with generalized chronic pruritus (> 6 weeks duration) and showing prurigo nodularis refractory to pretreatment with antihistamines (normal dosage, four weeks)
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004858 10037084 Prurigo nodularis LLT
    17.0 100000004858 10018123 Generalized pruritus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-002699-26 Sponsor Protocol Number: PREFECT Start Date*: 2015-10-08
    Sponsor Name:GWT-TUD GmbH
    Full Title: Pilot study of tolerability and effectivity following application of two combination topical acne products clindamycin 1% and 0.025% tretinoin gel (Acnatac® Gel), adapalen 0,1% and benzoyl peroxide...
    Medical condition: acne vulgaris
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-015090-12 Sponsor Protocol Number: 04082009 Start Date*: 2013-07-23
    Sponsor Name:Association of Dutch Burn Centres
    Full Title: Standard Treatment Or topical doxepin against Pruritus in burn patients
    Medical condition: Pruritus in patients with burns
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004863 10006799 Burns NOS LLT
    16.0 100000004858 10037090 Pruritus cutaneous LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-002083-27 Sponsor Protocol Number: KAD169 Start Date*: 2012-10-29
    Sponsor Name:Dr. Kade Pharmazeutische Fabrik GmbH
    Full Title: Placebo-controlled double-blind trial investigating the efficacy and tolerability of Posterisan® akut with lidocaine 60 mg/suppository in abatement of complaints associated with hemorrhoids
    Medical condition: Relief of complaints associated with hemorrhoids (pain, burning, itching)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004865 10002580 Anorectal therapeutic procedures HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-006283-42 Sponsor Protocol Number: KAD166 Start Date*: 2012-04-30
    Sponsor Name:Dr. Kade Pharmazeutische Fabrik GmbH
    Full Title: Placebo-controlled double-blind trial investigating the efficacy and tolerability of Posterisan® akut with lidocaine (50 mg/g rectal ointment) in abatement of complaints associated with the anorect...
    Medical condition: Relief of complaints associated with anorectal symptom complex (pain, burning, itching)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10002580 Anorectal therapeutic procedures HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-000684-10 Sponsor Protocol Number: ME3301-12 Start Date*: 2004-10-28
    Sponsor Name:Meiji Seika Kaisha, Ltd.
    Full Title: A randomised, double-blind, placebo-controlled crossover study to investigate the efficacy and safety of three doses of ME3301 in patients with seasonal allergic rhinitis during allergen challenge ...
    Medical condition: seasonal allergic rhinitis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000481-32 Sponsor Protocol Number: THYPOS Start Date*: 2016-05-03
    Sponsor Name:UNIVERSITÀ CAMPUS BIO-MEDICO DI ROMA
    Full Title: TERIPARATIDE FOR THE PRIMARY PREVENTION OF POST-SURGICAL HYPOCALCEMIA
    Medical condition: POST SURGICAL HYPOCALCEMIA
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10033557 Palpitations PT
    20.0 10047065 - Vascular disorders 10021097 Hypotension PT
    20.0 10040785 - Skin and subcutaneous tissue disorders 10037087 Pruritus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000998-72 Sponsor Protocol Number: 4083-006 Start Date*: 2019-01-22
    Sponsor Name:Kyowa Kirin Co., Ltd.
    Full Title: A Phase 2, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects with Moderate to Severe Atopic Dermatitis
    Medical condition: Moderate to Severe Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-024572-25 Sponsor Protocol Number: OCG-15/2010 Start Date*: 2011-03-22
    Sponsor Name:Dr. August Wolff GmbH & Co. KG Arzneimittel
    Full Title: Local antibacterial efficacy of a gel containing 0.1 % octenidine dihydrochloride on pre-damaged skin
    Medical condition: healthy volunteers antiseptic for repeated, temporarily limited antiseptic treatment of superficial skin injuries
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-004098-15 Sponsor Protocol Number: DS107G-04-UP1 Start Date*: 2018-01-30
    Sponsor Name:DS Biopharma
    Full Title: A Randomised, Double-blind, Placebo-controlled, Phase 2 Study to Assess the Efficacy and Safety of Orally Administered DS107 in a once daily dose of 2g in Haemodialysis Patients with Moderate to Se...
    Medical condition: Moderate to Severe Uremic Pruritus
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10060884 Uremic pruritus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Prematurely Ended) EE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-002931-25 Sponsor Protocol Number: VP-VLY-686-2101 Start Date*: 2013-11-05
    Sponsor Name:Vanda Pharmaceuticals Inc.
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF OF CONCEPT, ANTIPRURITIC STUDY OF THE NEUROKININ-1 RECEPTOR ANTAGONIST VLY-686 IN SUBJECTS WITH TREATMENT-RESISTANT PRURITUS ASSOCIATED WITH AT...
    Medical condition: Males or females with treatment resistant pruritus associated with atopic dermatitis.
    Disease: Version SOC Term Classification Code Term Level
    17.1 10040785 - Skin and subcutaneous tissue disorders 10037087 Pruritus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-005339-15 Sponsor Protocol Number: CAIN457A3302 Start Date*: 2015-05-29
    Sponsor Name:Novartis Pharma Services AG
    Full Title: Long term clear skin maintenance treatment optimization in patients with moderate to severe chronic plaque psoriasis: A randomized, multicenter, open-label with blinded-assessment, comparative, 52 ...
    Medical condition: Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) ES (Completed) IE (Completed) NL (Completed) CZ (Completed) SK (Completed) AT (Completed) BE (Completed) HU (Completed) SE (Completed) DE (Completed) BG (Completed) DK (Completed) FI (Completed) LV (Completed) LT (Completed) FR (Completed) GR (Completed) GB (Completed) PL (Completed) HR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-005628-41 Sponsor Protocol Number: TR03ext Start Date*: 2015-02-06
    Sponsor Name:Trevi Therapeutics, Inc.
    Full Title: An Open Label Extension Study of the Safety and Anti-Pruritic Efficacy of Nalbuphine HCL ER Tablets in Prurigo Nodularis Patients
    Medical condition: Prurigo Nodularis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10040785 - Skin and subcutaneous tissue disorders 10040785 Skin and subcutaneous tissue disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2008-007055-28 Sponsor Protocol Number: P-080623-01 Start Date*: 2009-06-04
    Sponsor Name:Ferrer International, SA
    Full Title: GF-001001-00 cream. A multicentre, randomised, double-blind, parallel, placebo-controlled phase II study to assess the efficacy and safety of 3 different doses of GF-001001-00 cream versus placebo...
    Medical condition: Secondarily-infected traumatic lesions
    Disease: Version SOC Term Classification Code Term Level
    9.1 10040872 Skin infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Completed) CZ (Completed) DE (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-002248-95 Sponsor Protocol Number: BOFT-0418-SAFE Start Date*: 2018-09-26
    Sponsor Name:FAES FARMA S.A.
    Full Title: Multi-centre, randomised, double blind, placebo-controlled, parallel, phase III study to assess the safety, tolerability and efficacy of bilastine ophthalmic solution 0.6% in adults
    Medical condition: Allergic Conjunctivitis (AC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10001709 Allergic conjunctivitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) HU (Completed) SK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-002416-41 Sponsor Protocol Number: 201000 Start Date*: 2017-02-17
    Sponsor Name:GlaxoSmithKline, S.A.
    Full Title: A randomized, double-blind, multi-dose, placebo-controlled study to evaluate the efficacy, safety and tolerability of GSK2330672 administration for the treatment of pruritus in patients with primar...
    Medical condition: Primary biliary cholangitis (PBC)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10019805 - Hepatobiliary disorders 10008604 Cholangitis PT
    19.0 10040785 - Skin and subcutaneous tissue disorders 10037087 Pruritus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 04 19:33:21 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA